SCISPARC LTD (SPRC) Fundamental Analysis & Valuation

NASDAQ:SPRC • IL0010951403

3.85 USD
-0.17 (-4.23%)
At close: Mar 11, 2026
3.93 USD
+0.08 (+2.08%)
Pre-Market: 3/12/2026, 9:06:09 AM

This SPRC fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

0

SPRC gets a fundamental rating of 0 out of 10. The analysis compared the fundamentals against 193 industry peers in the Pharmaceuticals industry. SPRC has a bad profitability rating. Also its financial health evaluation is rather negative. SPRC does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

1

1. SPRC Profitability Analysis

1.1 Basic Checks

  • SPRC had negative earnings in the past year.
  • SPRC had negative earnings in each of the past 5 years.
  • In the past 5 years SPRC always reported negative operating cash flow.
SPRC Yearly Net Income VS EBIT VS OCF VS FCFSPRC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -2M -4M -6M -8M -10M

1.2 Ratios

  • SPRC has a worse Return On Assets (-122.18%) than 79.27% of its industry peers.
Industry RankSector Rank
ROA -122.18%
ROE N/A
ROIC N/A
ROA(3y)-44.59%
ROA(5y)-65.61%
ROE(3y)-61.5%
ROE(5y)-99.8%
ROIC(3y)N/A
ROIC(5y)N/A
SPRC Yearly ROA, ROE, ROICSPRC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10K -20K -30K -40K

1.3 Margins

  • SPRC has a better Gross Margin (38.74%) than 62.18% of its industry peers.
  • The Profit Margin and Operating Margin are not available for SPRC so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 38.74%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SPRC Yearly Profit, Operating, Gross MarginsSPRC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600

0

2. SPRC Health Analysis

2.1 Basic Checks

  • SPRC does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for SPRC has been increased compared to 1 year ago.
  • Compared to 5 years ago, SPRC has more shares outstanding
  • Compared to 1 year ago, SPRC has an improved debt to assets ratio.
SPRC Yearly Shares OutstandingSPRC Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 100K 200K 300K 400K 500K
SPRC Yearly Total Debt VS Total AssetsSPRC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M

2.2 Solvency

  • SPRC has an Altman-Z score of -22.03. This is a bad value and indicates that SPRC is not financially healthy and even has some risk of bankruptcy.
  • With a Altman-Z score value of -22.03, SPRC is not doing good in the industry: 84.97% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -22.03
ROIC/WACCN/A
WACC8.59%
SPRC Yearly LT Debt VS Equity VS FCFSPRC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5M -5M -10M

2.3 Liquidity

  • A Current Ratio of 0.55 indicates that SPRC may have some problems paying its short term obligations.
  • SPRC's Current ratio of 0.55 is on the low side compared to the rest of the industry. SPRC is outperformed by 90.16% of its industry peers.
  • A Quick Ratio of 0.52 indicates that SPRC may have some problems paying its short term obligations.
  • The Quick ratio of SPRC (0.52) is worse than 88.08% of its industry peers.
Industry RankSector Rank
Current Ratio 0.55
Quick Ratio 0.52
SPRC Yearly Current Assets VS Current LiabilitesSPRC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M

0

3. SPRC Growth Analysis

3.1 Past

  • SPRC shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 91.42%, which is quite impressive.
  • The Revenue for SPRC has decreased by -54.64% in the past year. This is quite bad
EPS 1Y (TTM)91.42%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
Revenue 1Y (TTM)-54.64%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
SPRC Yearly Revenue VS EstimatesSPRC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2022 2023 2024 500K 1M 1.5M 2M 2.5M
SPRC Yearly EPS VS EstimatesSPRC Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 -0.2 -0.4 -0.6 -0.8 -1

0

4. SPRC Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for SPRC. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SPRC Price Earnings VS Forward Price EarningsSPRC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SPRC Per share dataSPRC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -5 -10 -15 -20

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

0

5. SPRC Dividend Analysis

5.1 Amount

  • SPRC does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

SPRC Fundamentals: All Metrics, Ratios and Statistics

SCISPARC LTD

NASDAQ:SPRC (3/11/2026, 8:25:54 PM)

Premarket: 3.93 +0.08 (+2.08%)

3.85

-0.17 (-4.23%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)04-24
Earnings (Next)N/A
Inst Owners1.32%
Inst Owner Change0%
Ins Owners19.81%
Ins Owner ChangeN/A
Market Cap16.75M
Revenue(TTM)1.31M
Net Income(TTM)-6.28M
AnalystsN/A
Price TargetN/A
Short Float %4.53%
Short Ratio0.12
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 12.82
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-22.63
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0.3
BVpS-0.18
TBVpS-0.5
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -122.18%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 38.74%
FCFM N/A
ROA(3y)-44.59%
ROA(5y)-65.61%
ROE(3y)-61.5%
ROE(5y)-99.8%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset Turnover0.25
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.55
Quick Ratio 0.52
Altman-Z -22.03
F-ScoreN/A
WACC8.59%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)91.42%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-54.64%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-3.46%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y13.41%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y13.41%
OCF growth 3YN/A
OCF growth 5YN/A

SCISPARC LTD / SPRC FAQ

Can you provide the ChartMill fundamental rating for SCISPARC LTD?

ChartMill assigns a fundamental rating of 0 / 10 to SPRC.


What is the valuation status of SCISPARC LTD (SPRC) stock?

ChartMill assigns a valuation rating of 0 / 10 to SCISPARC LTD (SPRC). This can be considered as Overvalued.


How profitable is SCISPARC LTD (SPRC) stock?

SCISPARC LTD (SPRC) has a profitability rating of 1 / 10.